Chang Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chang Lu has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Dengtang Liu
Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications Jingxin Xue
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publicationsQiong Xiang
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publicationsYuqing Zhao
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publicationsZhaolin Zhai
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publicationsDi Chang
Shanghai Jiao Tong University School of Medicine
2 shared publications
Latest Publications
- Open Access
Nucleus Accumbens-Anterior Limb of Internal Capsule Deep Brain Stimulation for Treatment-Resistant Schizophrenia: An Open-label Pilot Study
We conducted an open-label pilot study of bilateral nucleus accumbens-anterior limb of the internal capsule (NAc-ALIC) deep brain stimulation (DBS) in three patients with treatment-resistant schizophrenia (TRS). Clinical symptoms, global functioning, cognition, stimulation parameters and intracranial local field potential (LFP) were assessed over 24 weeks. Two patients met the prespecified clinical response criterion, defined as a ≥40% reduction in Positive and Negative Syndrome Scale (PANSS) total score, by week 8 and showed PANSS reductions of 69.0% and 69.4%, respectively, at week 24. The third patient showed a 18.7% reduction at week 24. Responders showed improvements in global functioning and selected cognitive domains. Longitudinal LFP recordings revealed increased gamma-band relative power and reduced theta-band activity in responders, whereas these changes were less consistent in the non-responder. DBS was generally well tolerated, with transient stimulation-related adverse effects resolving after reprogramming. These findings provide preliminary clinical evidence supporting further investigation of NAc-ALIC DBS in TRS and suggest that individualized programming and intracranial physiological measures may contribute to the identification of treatment-response signatures. Registration: NCT06112067 in ClinicalTrial.gov
Open AccessNucleus Accumbens-Anterior Limb of Internal Capsule Deep Brain Stimulation for Treatment-Resistant Schizophrenia: An Open-label Pilot Study
We conducted an open-label pilot study of bilateral nucleus accumbens-anterior limb of the internal capsule (NAc-ALIC) deep brain stimulation (DBS) in three patients with treatment-resistant schizophrenia (TRS). Clinical symptoms, global functioning, cognition, stimulation parameters and intracranial local field potential (LFP) were assessed over 24 weeks. Two patients met the prespecified clinical response criterion, defined as a ≥40% reduction in Positive and Negative Syndrome Scale (PANSS) total score, by week 8 and showed PANSS reductions of 69.0% and 69.4%, respectively, at week 24. The third patient showed a 18.7% reduction at week 24. Responders showed improvements in global functioning and selected cognitive domains. Longitudinal LFP recordings revealed increased gamma-band relative power and reduced theta-band activity in responders, whereas these changes were less consistent in the non-responder. DBS was generally well tolerated, with transient stimulation-related adverse effects resolving after reprogramming. These findings provide preliminary clinical evidence supporting further investigation of NAc-ALIC DBS in TRS and suggest that individualized programming and intracranial physiological measures may contribute to the identification of treatment-response signatures. Registration: NCT06112067 in ClinicalTrial.gov
- Open Access
- 22 June 2026
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 56, e203
Predicting functional remission after antipsychotic discontinuation: a real-world study in schizophrenia – ERRATUM
- 22 June 2026
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 56, e203
Open AccessPredicting functional remission after antipsychotic discontinuation: a real-world study in schizophrenia – ERRATUM
- Open Access
- 28 May 2026
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 56, e167
Predicting functional remission after antipsychotic discontinuation: a real-world study in schizophrenia
Background: This real-world study aimed to characterize patients with schizophrenia who achieve sustained good functional outcomes after antipsychotic discontinuation and to develop the Functional Remission in Schizophrenia after Antipsychotic Discontinuation (FURSAD) predictive model. Methods: We retrospectively identified individuals aged 18–65 years with schizophrenia (ICD-10) from the Shanghai Mental Health Center discharge database. Patients who discontinued antipsychotics for ≥1 year were classified as functional remission (FR) or functional non-remission (FNR) based on functioning assessments. Sociodemographic, clinical, and treatment-related data were extracted blindly from hospital records and structured interviews. Results: Among 4,166 discharged patients screened, 180 met the inclusion criteria (FR: 116; FNR: 64). Six independent predictors were identified: total disease course, Clinical Global Impression-Severity (CGI-S) score, Positive and Negative Syndrome Scale (PANSS) emotional distress subscale score, use of first-generation antipsychotics, discontinuation due to treatment benefits, and discontinuation due to lack of insight. The logistic regression model showed strong predictive performance (AUC = 0.867, 95% CI 0.813–0.921), with 82.8% sensitivity and 81.9% specificity. Internal validation was performed via 10-fold cross-validation. Conclusion: Discontinuation motives and illness trajectory are relevant in predicting long-term functional outcomes. A limitation is that a substantial number of patients could not be recontacted or declined participation, which may introduce selection bias. The FURSAD nomogram may help clinicians estimate the probability of FR 4.5 years post-antipsychotic discontinuation in patients previously on antipsychotics for ≥3 years.
- 28 May 2026
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 56, e167
Open AccessPredicting functional remission after antipsychotic discontinuation: a real-world study in schizophrenia
Background: This real-world study aimed to characterize patients with schizophrenia who achieve sustained good functional outcomes after antipsychotic discontinuation and to develop the Functional Remission in Schizophrenia after Antipsychotic Discontinuation (FURSAD) predictive model. Methods: We retrospectively identified individuals aged 18–65 years with schizophrenia (ICD-10) from the Shanghai Mental Health Center discharge database. Patients who discontinued antipsychotics for ≥1 year were classified as functional remission (FR) or functional non-remission (FNR) based on functioning assessments. Sociodemographic, clinical, and treatment-related data were extracted blindly from hospital records and structured interviews. Results: Among 4,166 discharged patients screened, 180 met the inclusion criteria (FR: 116; FNR: 64). Six independent predictors were identified: total disease course, Clinical Global Impression-Severity (CGI-S) score, Positive and Negative Syndrome Scale (PANSS) emotional distress subscale score, use of first-generation antipsychotics, discontinuation due to treatment benefits, and discontinuation due to lack of insight. The logistic regression model showed strong predictive performance (AUC = 0.867, 95% CI 0.813–0.921), with 82.8% sensitivity and 81.9% specificity. Internal validation was performed via 10-fold cross-validation. Conclusion: Discontinuation motives and illness trajectory are relevant in predicting long-term functional outcomes. A limitation is that a substantial number of patients could not be recontacted or declined participation, which may introduce selection bias. The FURSAD nomogram may help clinicians estimate the probability of FR 4.5 years post-antipsychotic discontinuation in patients previously on antipsychotics for ≥3 years.